Singapore - engelsk - HSA (Health Sciences Authority)

gn hearing pte. ltd. - ear, nose & throat - generic air-conductionhearing aids are wearable sound-amplifying devices intended to compensate for impaired hearing. the fundamental operatingprinciple of hearing aids is to receive, amplify, and transfer sound to the eardrum of a hearing-impaired person.

Singapore - engelsk - HSA (Health Sciences Authority)

gn hearing pte. ltd. - ear, nose & throat - generic air-conductionhearing aids are wearable sound-amplifying devices intended to compensate for impaired hearing. the fundamental operating principle of hearing aids is to receive, amplify, and transfer sound to the eardrum of a hearing-impaired person.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levetiracetam -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - carvedilol -

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

gn neutriceuticals sdn bhd - lactobacillus bulgaricus; lactobacillus casei; streptococcus thermophilus; bifidobacterium longum; lactobacillus acidophilus -

Østerrike - tysk - AGES (Agentur für Gesundheit und Ernährungssicherheit)

generinobel gmbh - escitalopram oxalat -

Østerrike - tysk - AGES (Agentur für Gesundheit und Ernährungssicherheit)

generinobel gmbh - escitalopram oxalat -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; hypromellose; macrogol 400 - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory idiopathic thrombocytopenic purpura.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - azathioprine, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400; macrogol 8000; sunset yellow fcf aluminium lake; carmine; indigo carmine aluminium lake - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumetoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory idiopathic thromocytopenic purpura.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: water for injections; ethanol absolute; citric acid; polysorbate 80 - 1. breast cancer a) metastatic breast cancer,gn-docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. gn-docetaxel injection in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. gn-docetaxel injection in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,b). adjuvant treatment of breast cancer,gn-docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by gn-docetaxel injection in combination with trastuzumab (ac- th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. gn-docetaxel injection in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. gn-docetaxel injection in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1cm and < 7cm.,2. non small cell lung cancer,gn-docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,3.ovarian cancer,gn-docetaxel injection is indicated for the treatment of metastatic carcinoma of the ovary after failure of first- line or subsequent chemotherapy.,4.prostate cancer,gn-docetaxel injection is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,5. head and neck cancer,gn-docetaxel injection, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.